$HAE

US Stock Movers: HAE Surges 17% While AAOI and ARGX Lead Thursday's Losers

On 8 October 2026, Haemonetics (HAE) rose 17.46% to $119.47, while Applied Optoelectronics (AAOI) fell 13.58% to $105.90. Other notable movers included Veradermics (MANE), Securitize (SECZ), The Vita Coco Company (COCO), Erasca (ERAS), MaxLinear (MXL), argenx (ARGX), EquipmentShare.com (EQPT), and Hut 8 (HUT).

Original reporting
Published Oct 8, 2026, 8:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 3:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
US Stock Movers: HAE Surges 17% While AAOI and ARGX Lead Thursday's Losers — source image
Decision brief

The 30-second read

$HAEBullishLow
01

Why it matters

Provides a snapshot of market volatility with double‑digit moves across diverse sectors, useful for short‑term traders.

02

Market read

Significant single‑day price moves highlight sector‑specific catalysts and overall market volatility, informing short‑term trading decisions.

03

What to watch

Potential hidden catalysts such as earnings whispers or supply‑chain news were not disclosed, possibly driving the moves.

Relevance 4/10Novelty 2/10Timing: after-hours

Background

The article lists notable intraday price moves for a set of U.S.-listed companies on October 8, 2026.

Company-level read

Ticker impact

$HAEBullishHigh confidence
Context

Shares surged 17.46% to $119.47, the headline mover of the day.

Expected impact

upward pressure as momentum continues

Evidence & confidence

Large intraday gain indicates bullish sentiment.

$MANEBullishHigh confidence
Context

Veradermics rose 14.13% to $126.63.

Expected impact

upward pressure from strong price action

Evidence & confidence

Significant move suggests continued buying interest.

$SECZBullishHigh confidence
Context

Securitize climbed 11.05% to $12.66.

Expected impact

upward pressure as crypto‑related demand persists

Evidence & confidence

Double‑digit gain reflects market optimism for blockchain platforms.

$COCOBullishHigh confidence
Context

The Vita Coco Company gained 10.52% to $55.98.

Expected impact

upward pressure from consumer‑goods rally

Evidence & confidence

Broad consumer‑stock strength lifts the ticker.

$ERASBullishHigh confidence
Context

Erasca closed 9.49% higher at $15.46.

Expected impact

upward pressure as biotech optimism persists

Evidence & confidence

Biotech sector momentum drives the rise.

$AAOIBearishHigh confidence
Context

Applied Optoelectronics fell 13.58% to $105.90.

Expected impact

downward pressure as sell‑off continues

Evidence & confidence

Sharp decline signals bearish sentiment.

$MXLBearishHigh confidence
Context

MaxLinear shed 12.72% to $93.70.

Expected impact

downward pressure from sector weakness

Evidence & confidence

Semiconductor weakness drags the stock lower.

$ARGXBearishHigh confidence
Context

argenx dropped 11.83% to $818.63.

Expected impact

downward pressure as biotech sell‑off spreads

Evidence & confidence

Biotech sector pullback impacts the ticker.

Market effects

Medical‑tech, blockchain, consumer, semiconductor and biotech sectors all showed heightened intra‑day volatility.

U.S. equities displayed broad volatility, reflecting mixed sector‑specific catalysts.

The sharp moves may influence risk sentiment in other markets tracking U.S. equity momentum.

Counterpoint

The large intraday swings could be over‑reactions; mean‑reversion may present buying opportunities on the losers.

Key entities

  • Haemonetics Corporation

    Medical‑technology firm

  • Applied Optoelectronics, Inc.

    Optoelectronics manufacturer

  • argenx SE

    Biotech company

Related articles

$GLXYHigh

Citi Upgrades Galaxy Digital Stock, Raises Price Target to $28

Citi upgraded Galaxy Digital (GLXY) to Buy, raising its price target to $28, citing strong AI infrastructure prospects and data center performance. The target implies 40.9% upside from the stock's last close. Citi also adjusted ratings for Coinbase (COIN), Gemini (GEMI), and Securitize (SECZ), with mixed outlooks. GLXY shares fell 2% despite the upgrade.

Low

Argenx Stops Phase 3 Vyvgart Trial in Sjögren's Disease After Monitors Find the Study Cannot Meet Its Goal

Argenx halted its Phase 3 UNITY trial of efgartigimod for Sjögren's disease after monitors found it unlikely to meet its primary goal. The decision, announced Oct. 8, was based on an interim analysis showing futility, not safety concerns. The drug remains approved for other conditions. Argenx plans to analyze the data and share findings. According to William Blair analysts, the trial included over 500 of 630 enrolled patients.

$SECZMed

Securitize Price Target Rises 50% to $18 at StoneX

StoneX raised its price target for Securitize (NYSE: SECZ) to $18 from $12, citing its expansion into blockchain-based securities markets. The company launched a platform for trading tokenized U.S. stocks, including Apple, Nvidia, Microsoft, and Tesla. Securitize reported $4.3B in tokenized assets under management and $5.3B in transaction volume, but revenue declined 5% to $14.4M with a net loss of $21.7M.

MedAI 8/10

Sandisk and MaxLinear: Rising Stars in Tech Stocks

Sandisk reported 372% YoY revenue growth in Q4 2026, with Q1 2027 projections at 20% sequential growth. MaxLinear saw 55% YoY revenue growth in Q2 2027, with Q3 guidance up to $220M. Both companies are positioned in high-demand tech sectors, with Sandisk in NAND flash memory and MaxLinear in AI-driven data center microchips.

$SECZMed

Apple, Nvidia, and Tesla Shares Now Trade on Solana: Why Did Securitize Choose Solana Over Ethereum?

Securitize (NYSE:SECZ) launched tokenized stocks on Solana (CRYPTO:SOL), including shares of Apple (NASDAQ:AAPL), Nvidia (NASDAQ:NVDA), and Tesla (NASDAQ:TSLA). Each token is backed 1:1 by a share, and Securitize's stock surged over 10% after the announcement. Solana was chosen for its fast and affordable trading, with minimal network fees. However, SOL's price did not see a significant increase following the launch.

$ARGXMed

argenx Meets Primary Endpoint in Phase II Celiac Disease Study

argenx reported positive phase II results for FB102, a treatment for celiac disease, meeting its primary endpoint. The study showed significant improvement in intestinal damage compared to placebo. Despite this, shares fell 12% due to another announcement. argenx plans to advance FB102 into late-stage development. The company also has other autoimmune disease treatments in development.